ArticleJournal of translational medicine2025
Plasma multi-omics and machine learning reveal predictive biomarkers for type 2 diabetes and retinopathy in Qatar biobank cohort.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial intelligence in biomarker discovery for diseases: diagnostic and therapeutic prospects.Signal transduction and targeted therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundType 2 diabetes (T2D) and its vascular complications, including diabetic retinopathy (DR), are escalating in prevalence globally, with disproportionately high prevalence in Middle Eastern populations, where genetic predispositions and lifestyle factors intersect. Early detection and precise risk stratification remain critical challenges in this region. We hypothesised that an integrated plasma multi-omics profile; comprising microRNA, mRNA, and protein biomarkers, could accurately distinguish individuals with T2D and its complications in a Middle Eastern cohort.
methodsA candidate panel of mRNA and protein biomarkers identified from in vitro hyperglycaemia models, along with a vascular microRNA signature previously defined in an Australian cohort, was evaluated. These multiomic biomarkers were profiled in 962 individuals (492 controls, 434 T2D and 36 T2D with DR) from the Qatar Biobank (QBB). Random Forest machine learning workflow was used for risk stratification, with model performance assessed by accuracy and area under the receiver operating characteristic curve. SHAP analysis and penalised regression were used to identify key discriminative biomarkers.
resultsThe Random Forest classifier achieved robust performance, with an AUC of 0.83, F1 score of 0.78, and overall accuracy of 0.76 in distinguishing T2D cases from controls. A regulatory axis involving miR-29c (protective) and PROM1 (risk-promoting) was identified as a central driver for T2D and DR progression. Protein biomarkers, including ANGPT2 (fold change = 1.64, p-value = 3.8e-03) and PlGF (fold change = 0.66, p-value = 3.7e-02), were significantly associated with vascular complications.
conclusionsIntegrating multi-omics data with machine learning enables accurate risk stratification for T2D and DR in Middle Eastern populations. The miR-29c-PROM1 axis and associated proteins represent promising biomarkers for early detection and targeted intervention. Leveraging QBB resources, this study lays the groundwork for precision health initiatives aimed at mitigating diabetes-related complications in a high-risk Middle Eastern cohort.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.